THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, January 31, 2022
The pharmaceutical industry has become increasingly enthusiastic about technological advancements over the last decade, as it has the potential to substantially shorten the time it takes to develop a new medicine.
FREMONT, CA: While there has been a lot of progress in drug development over the last decade, notably with artificial intelligence (AI) and machine learning technologies geared at streamlining and removing risks from the drug development process, it is only the beginning. As we enter a new decade, we may expect more technological advancements, more pharmaceutical-technology partnerships, and new clinical trial methods to speed up drug development. In the coming years, data sharing should become more common. Beyond technology advancements such as artificial intelligence (AI) and machine learning for drug discovery and early development, clinical trial models will evolve to cut costs and expedite the approval of prospective medicines.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Artificial Intelligence (AI) to monitor data
AI can manage a lot of data and be used for things like target identification, big data analytics, forecasting, patient matching, and automated chemical creation, among other things. Several pharmaceutical companies have embraced and used AI technologies like machine learning, betting big that AI would cut costs, shorten timeframes, and lead to new and better treatments. AI's ability to support and analyze large volumes of data is a crucial premise. We're barely scratching the surface of AI's potential in data collection. Adopting AI technology is as much about the human-data interface change management process as technology. Drug development has the potential to be transformed if AI is used correctly.
Technology collaborations will continue to grow in popularity
In the next ten years, digital technology and biopharmaceutical business collaborations will continue to gain popularity in methods that aim to expedite and streamline the drug development process while getting critical medicine to patients who need it most. Pharmaceutical/technology collaborations, at their most basic level, assist pharmaceutical companies in adopting a more agile approach to drug development, even before actual benefits to the development process are apparent. These partnerships could lead to more efficient and cost-effective bench-to-bedside solutions.
Enhanced clinical trial models
Virtual clinical trials are becoming more popular as a strategy to cut costs and reduce patient burden while enhancing patient retention by making trials and treatments as accessible and appealing to patients as feasible. Clinical studies that are done virtually allow for a more patient-centred approach. Virtual clinical trials will become more popular in the coming decade as technological advances make it possible to gather, monitor, and aggregate data more rapidly and effectively from afar. Virtual clinical trial models, artificial intelligence, and technological partnerships are just a few of the key themes that will impact drug development in the coming decade, accelerating the delivery of much-needed medications to patients.
More in News